{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:30:23Z","timestamp":1792985423930,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1038\/s41571-024-00927-6","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T14:02:09Z","timestamp":1721397729000},"page":"707-708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["BCMA-directed therapy for early relapsed and\/or refractory multiple myeloma"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-2603","authenticated-orcid":false,"given":"Niels W. C. J.","family":"van de Donk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"key":"927_CR1","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"NWCJ van de Donk","year":"2021","unstructured":"van de Donk, N. W. C. J., Pawlyn, C. & Yong, K. L. Multiple myeloma. Lancet 397, 410\u2013427 (2021).","journal-title":"Lancet"},{"key":"927_CR2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405090","author":"V Hungria","year":"2024","unstructured":"Hungria, V. et al. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2405090 (2024).","journal-title":"N. Engl. J. Med."},{"key":"927_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407","author":"MA Dimopoulos","year":"2024","unstructured":"Dimopoulos, M. A. et al. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2403407 (2024).","journal-title":"N. Engl. J. Med."},{"key":"927_CR4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207\u2013221 (2020).","journal-title":"Lancet Oncol."},{"key":"927_CR5","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1002\/cncr.33809","volume":"127","author":"S Lonial","year":"2021","unstructured":"Lonial, S. et al. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study. Cancer 127, 4198\u20134212 (2021).","journal-title":"Cancer"},{"key":"927_CR6","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos, M. A. et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 10, e801\u2013e812 (2023).","journal-title":"Lancet Haematol."},{"key":"927_CR7","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N. Engl. J. Med."},{"key":"927_CR8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel, J. et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N. Engl. J. Med. 389, 335\u2013347 (2023).","journal-title":"N. Engl. J. Med."},{"key":"927_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","volume":"402","author":"NWCJ van de Donk","year":"2023","unstructured":"van de Donk, N. W. C. J. & Zweegman, S. T-cell-engaging bispecific antibodies in cancer. Lancet 402, 142\u2013158 (2023).","journal-title":"Lancet"},{"key":"927_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00094-9","author":"Y Lin","year":"2024","unstructured":"Lin, Y. et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(24)00094-9 (2024).","journal-title":"Lancet Oncol."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00927-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00927-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00927-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T13:02:40Z","timestamp":1726837360000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-024-00927-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["927"],"URL":"https:\/\/doi.org\/10.1038\/s41571-024-00927-6","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,19]]},"assertion":[{"value":"19 July 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.W.C.J.v.d.D. has received research support via his institution from Amgen, Bristol Myers Squibb (BMS), Celgene, Cellectis, Janssen and Novartis, and serves on advisory boards for AbbVie, Adaptive Biotech, Amgen, Bayer, BMS, Celgene, Janssen, Kite Pharma, Merck, Novartis, Pfizer, Roche, Sanofi, Servier and Takeda. S.Z. has received research support via her institution from Janssen and Takeda, and serves on advisory boards for BMS, GSK, Janssen, Oncopeptides, Sanofi and Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}